Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Key facts

Sponsor

Arkadiusz Z. Dudek, MD

Principal Investigator

Arkadiusz Z Dudek, M.D., Ph.D.

Big Ten Cancer Research Consortium

Intervention

MK-3475(drug)

Enrollment

61 enrolled

Eligibility

18 years · All sexes

Timeline

2015 – 2019

Study locations (9)

• Northwestern University, Robert H. Lurie Cancer Center, Chicago, Illinois, United States
• University of Illinois Cancer Center, Chicago, Illinois, United States
• University of Iowa, Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
• University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
• Michigan State University, Breslin Cancer Center, Lansing, Michigan, United States
• University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States
• University of Nebraska, Fred and Pamela Buffet Cancer Center, Omaha, Nebraska, United States
• Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
• Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States

Collaborators

Merck Sharp & Dohme LLC · Big Ten Cancer Research Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →